Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Ozurdex® assessment for diabetic macular edema: OZDIME study

Poster Details

First Author: P.Ruiz-De la Fuente SPAIN

Co Author(s):    A. Pareja-Rios   A. Blasco-Alberto   Y. Gonzalez-Mora   V. Lozano-López     

Abstract Details


To evaluate the efficiency and safety of intravitreal implant of 0.7mg dexamathasone in the treatment of patients with diabetic macular edema (DME).


Hospital Universitario de Canarias in La Laguna, Tenerife (Canary Islands)


This was a retrospective study. Patients (n = 110) with DME, with a mean age of 67.4 years. 87.3% type 2 diabetics. 43.6% were obese and 73.4% had hypertension. The patients were followed for at least 12 months were included between 12 months. 49.5% of patients had received previous macular laser, 32% with intravitreal anti-VEGF treatment and 10.8% other treatments, with only 7.7% naive patients. The mean HbA1c was 7.8%. Best-corrected visual acuity (BCVA), central retinal thickness (Cirrus-HD OCT), intraocular pressure (IOP) and cataract progression are studied at baseline and then at 1, 2, 4, 6 and 12 months.


The average CRT decrease was: 118,18μm between month 2 and 3 (M2-3) and 66,54 μm at month 4 (M4). At month 7 (M7) the average CRT was the same than before the dexamethasone implant (461,98). The mean improvement from baseline of BCVA is 0.18 Snellen at M2-3 and 0.05 at M6. The visual acuity not return to the level prior to implantation of dexamethasone during the first year. The average visual acuity is always kept at least 0.05 above the initial vision. The peak of intraocular pressure seen between the second and third month. No glaucoma surgery was necessary


Dexamethasone has an anatomical and functional effectiveness in the treatment of DME. Side effects are rare and manageable. Ozurdex(®) seems to be a treatment for visual impairment due to DME with a favorable safety profile. Patient follow-up must be adapted to half-life of the product with a control before M1 (intraocular pressure) and before M5 (DME recurrence, BCVA).

Financial Disclosure:


Back to Poster listing